Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Implant or insert
Reexamination Certificate
2008-04-15
2008-04-15
Kennedy, Sharon E. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Implant or insert
C514S291000, C514S449000
Reexamination Certificate
active
11464676
ABSTRACT:
A system and compositions including zotarolimus and paclitaxel are disclosed, as well as methods of delivery, wherein the drugs have effects that complement each other. Medical devices are disclosed which include supporting structures that include at least one pharmaceutically acceptable carrier or excipient, which carrier or excipient can include one or more therapeutic agents or substances, with the carrier including at least one coating on the surface thereof, and the coating associated with the therapeutic substances, such as, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include, but are not limited to, coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. These compositions and systems can be used in combination with other drugs, including anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, anti-lipaedemic agents, matrix metalloproteinase inhibitors, cytostatic drugs, or combinations of these and other drugs.
REFERENCES:
patent: 3929992 (1975-12-01), Sehgal
patent: 3993749 (1976-11-01), Sehgal
patent: 4316885 (1982-02-01), Rakhit
patent: 4401653 (1983-08-01), Eng
patent: 4650803 (1987-03-01), Stella
patent: 4885171 (1989-12-01), Surendra
patent: 4916193 (1990-04-01), Tang
patent: 4994071 (1991-02-01), MacGregor
patent: 5023262 (1991-06-01), Caufield
patent: 5092877 (1992-03-01), Pinchuk
patent: 5120725 (1992-06-01), Kao
patent: 5120727 (1992-06-01), Kao
patent: 5120842 (1992-06-01), Failli
patent: 5163952 (1992-11-01), Froix
patent: 5177203 (1993-01-01), Failli
patent: 5304121 (1994-04-01), Sahatjian
patent: 5447724 (1995-09-01), Helmus
patent: 5457111 (1995-10-01), Luly
patent: 5464650 (1995-11-01), Berg
patent: 5516781 (1996-05-01), Morris
patent: 5527337 (1996-06-01), Stack
patent: 5563146 (1996-10-01), Morris
patent: 5605696 (1997-02-01), Eury
patent: 5624411 (1997-04-01), Tuch
patent: 5646160 (1997-07-01), Morris
patent: 5665728 (1997-09-01), Morris
patent: 5705583 (1998-01-01), Bowers
patent: 6015815 (2000-01-01), Mollison
patent: 6090901 (2000-07-01), Bowers
patent: 6273913 (2001-08-01), Wright
patent: 6284305 (2001-09-01), Ding
patent: 6358556 (2002-03-01), Ding
patent: 6413272 (2002-07-01), Igaki
patent: 6419692 (2002-07-01), Yang
patent: 6585764 (2003-07-01), Wright
patent: 2003/0129215 (2003-07-01), Mollison
patent: 2005/0004661 (2005-01-01), Lewis
patent: 2005/0019404 (2005-01-01), Sung Hsing-Wen et al.
patent: 2005/0175660 (2005-08-01), Mollison et al.
patent: 2005/0288481 (2005-12-01), Desnoter et al.
patent: 0184162 (1986-06-01), None
patent: 0 467 606 (1992-01-01), None
patent: WO 92/05179 (1992-04-01), None
patent: 01/87372 (2001-11-01), None
patent: 02/055122 (2002-07-01), None
patent: WO 2005/110508 (2005-11-01), None
patent: WO 2007/032777 (2007-03-01), None
patent: WO 2007/046935 (2007-04-01), None
patent: WO 2007/047416 (2007-04-01), None
Aggarwal, A., D.J. Schneider, B.E. Sobel, and H.L. Dauerman. 2003 Comparison of inflammatory markers in patients with diabetes mellitus versus those without before and after coronary arterial stenting. Am J Cardiol. 92:924-9.
Baker, H., A. Sidorowicz, S.N. Sehgal, and C. Vezina. 1978. Rapamycin (AY-22,989), a new antifungal antibiotic. III. In vitro and in vivo evaluation. J Antibiot (Tokyo). 31:539-45.
Bierer, B.D., S.L. Schreiber, and S.J. Burakoff. 1991. The effect of the immunosuppressant FK-506 on alternate pathways of T cell activation. Eur J Immunol. 21:439-45.
Biondi-Zoccai, G.G., A. Abbate, G. Liuzzo, and L.M. Biasucci. 2003. Atherothrombosis, inflammation, and diabetes. J Am Coll Cardiol. 41:1071-7.
Brown, E.J., M.W. Albers, T.B. Shin, K. Ichikawa, C.T. Keith, W.S. Lane, and S.L. Schreiber. 1994. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature. 369:756-8.
Bunchman, T.E., and C.A. Brookshire. 1991. Smooth muscle cell proliferation by conditioned media from cyclosporine-treated endothelial cells: a role of endothelin. Transplant Proc. 23:967-8.
Carter, A.J., M. Aggarwal, G.A. Kopia, F. Tio, P.S. Tsao, R. Kolata, A.C. Yeung, G. Llanos, J. Dooley, and R. Falotico. 2004. Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc Res. 63:617-24.
Dandona, P., and A. Aljada. 2002. A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and atherosclerosis. Am J Cardiol. 90:27G-33G.
Dumont, F.J., M.R. Melino, M.J. Staruch, S.L. Koprak, P.A. Fischer, and N.H. Sigal. 1990 The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells. J Immunol. 144:1418-24.
Fretz, H., M. Albers, A. Gala, R. Standaert, W. Lane, S. Burakoff, B. Bierer, and S. Schreiber. 1991. Rapamycin and FK506 binding proteins (immunophilins). J. Am. Chem. Soc. 113:1409-1411.
Grech, E.D., and D.R. Ramsdale. 2003 Acute coronary syndrome: unstable angina and non-ST segment elevation myocardial infarction. British Med. J. 326:1259-61.
Harding, M.W., A. Galat, D.E. Uehling, and S.L. Schreiber. 1989. A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. Nature. 341:758-60.
Hayward, C., D. Yohannes, and S. Danishefsky. 1993. Total synthesis of rapamycin via a novel titanium-mediated aldol macrocyclization reaction. J. Am. Chem. Soc. 115:9345-9346.
Helmus, M. 1990. Medical Device Design—A Systems Approach: Central Venous Catheters. In 22nd International Society for the Advancement of Material and Process Engineering Technical Conference.
Ji, Q., M. Reimer, and T. El-Shourbagy. 2004. 96-well liquid—liquid extraction liquid chromatography-tandem mass spectrometry method for the quantitative determination of ABT-578 in human blood samples. Journal of Chromatography B. 805:67-75.
Kino, T., N. Inamura, F. Sakai, K. Nakahara, T. Goto, M. Okuhara, M. Kohsaka, H. Aoki, and T. Ochiai. 1987. Effect of FK-506 on human mixed lymphocyte reaction in vitro. Transplant Proc. 19:36-9.
Kornowski, R., M.K. Hong, F.O. Tio, O. Bramwell, H. Wu, and M.B. Leon. 1998. In-stent restenosis: contributions of inflammatory responses and arterial injuy to neointimal hyperplasia. J Am Coll Cardiol. 31:224-30.
Martel, R.R., J. Klicius, and S. Galet. 1977. Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can J Physiol Pharmacol. 55:48-51.
Morris, R. 1992. Rapamycins: antifungal, antitumor, antiproliferative, and immunosuppressive macrolides. Transplant. Rev. 6:39-87.
Morris, R., and B. Meiser. 1989. Identification of a new pharmacologic action for an old compound. Med. Sci. Res. 17:609.
Nicolaou, K., T. Chakraborty, A Piscopio, N. Minowa, and P. Bertinato. 1993. Total synthesis of rapamycin. J. Am. Chem. Soc. 115:4419-4420.
Paiva, N.L., A.L. Demain, and M.F. Roberts. 1991, Incorporation of acetate, propionate, and methionine into rapamycin byStreptomyces hygroscopicus. J Nat Prod. 54:167-77.
Roffi, M., and E.J. Topol. 2004. Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes. Eur. Heart J. 25:190-8.
Romo, D., S. Meyer, D. Johsnon, and S. Schrieber. 1993. Total synthesis of (−)-rapamycin using an Evans-Tishchenko fragment coupling. J. Am. Chem. Soc. 115:7906-7907.
Sabatini, D.M., H. Erdjument-Bromage, M. Lui, P. Tempst, and S.H. Snyder. 1994. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell. 78:35-43.
Schwartz, R. 1992. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol. 19:267-274.
Sehgal, S.N., H. Baker, C.P. Eng, K. Singh, and C. Vezina. 1983. Demethoxyrapamycin (AY-24,668), a new antifungal antibiotic. J Antibiot (Tokyo). 36:351-4.
Sehgal, S.N., H. Baker, and C. Vezina. 1975. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fe
Burke Sandra E.
Cromack Keith R.
Mack Matthew
Toner John L.
Abbott Laboratories
Kennedy Sharon E.
Squire Sanders & Dempsey LLP
LandOfFree
Compositions, systems, and kits for administering... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions, systems, and kits for administering..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions, systems, and kits for administering... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3920266